5' Nucleotidase - Pipeline Review, H1 2020
5' Nucleotidase - Pipeline Review, H1 2020
SUMMARY
According to the recently published report '5' Nucleotidase – Pipeline Review, H1 2020'; 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) pipeline Target constitutes close to 34 molecules. Out of which approximately 31 molecules are developed by companies and remaining by the universities/institutes.
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) – 5?-Nucleotidase (5NT) is an intrinsic membrane glycoprotein that is present as an enzyme in a wide variety of mammalian cells. It catalyzes the phosphorylytic cleavage of 5'nucleotides.
The report '5' Nucleotidase – Pipeline Review, H1 2020' outlays comprehensive information on the 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 4, 1, 16 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Report covers products from therapy areas Oncology which include indications Solid Tumor, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Melanoma, Triple-Negative Breast Cancer (TNBC), Breast Cancer, Colorectal Cancer, Kidney Cancer (Renal Cell Cancer), Prostate Cancer, Colon Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Pancreatic Ductal Adenocarcinoma, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Gastric Cancer, Hepatocellular Carcinoma, Lung Cancer, Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Lung Cancer, Metastatic Renal Cell Carcinoma, Muscle Invasive Bladder Cancer (MIBC), Non-Small Cell Lung Carcinoma, Renal Cell Carcinoma, Sarcomas and Uterine Cancer.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report '5' Nucleotidase – Pipeline Review, H1 2020'; 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) pipeline Target constitutes close to 34 molecules. Out of which approximately 31 molecules are developed by companies and remaining by the universities/institutes.
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) – 5?-Nucleotidase (5NT) is an intrinsic membrane glycoprotein that is present as an enzyme in a wide variety of mammalian cells. It catalyzes the phosphorylytic cleavage of 5'nucleotides.
The report '5' Nucleotidase – Pipeline Review, H1 2020' outlays comprehensive information on the 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 4, 1, 16 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Report covers products from therapy areas Oncology which include indications Solid Tumor, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Melanoma, Triple-Negative Breast Cancer (TNBC), Breast Cancer, Colorectal Cancer, Kidney Cancer (Renal Cell Cancer), Prostate Cancer, Colon Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Pancreatic Ductal Adenocarcinoma, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Gastric Cancer, Hepatocellular Carcinoma, Lung Cancer, Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Lung Cancer, Metastatic Renal Cell Carcinoma, Muscle Invasive Bladder Cancer (MIBC), Non-Small Cell Lung Carcinoma, Renal Cell Carcinoma, Sarcomas and Uterine Cancer.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5)
- The report reviews 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics and enlists all their major and minor projects
- The report assesses 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Overview
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Therapeutics Development
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Therapeutics Assessment
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Companies Involved in Therapeutics Development
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Drug Profiles
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Dormant Products
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Product Development Milestones
Appendix
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Overview
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Therapeutics Development
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Therapeutics Assessment
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Companies Involved in Therapeutics Development
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Drug Profiles
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Dormant Products
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1)
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Akeso Inc, H1 2020
Pipeline by Aprilbio Co Ltd, H1 2020
Pipeline by Arcus Biosciences Inc, H1 2020
Pipeline by AstraZeneca Plc, H1 2020
Pipeline by Aurigene Discovery Technologies Ltd, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Pipeline by Calithera Biosciences Inc, H1 2020
Pipeline by Corvus Pharmaceuticals Inc, H1 2020
Pipeline by Eli Lilly and Co, H1 2020
Pipeline by Eternity Bioscience Inc, H1 2020
Pipeline by Evotec SE, H1 2020
Pipeline by Gilead Sciences Inc, H1 2020
Pipeline by Harbour BioMed, H1 2020
Pipeline by I-Mab Biopharma Co Ltd, H1 2020
Pipeline by Innate Pharma SA, H1 2020
Pipeline by InteRNA Technologies BV, H1 2020
Pipeline by iOnctura SA, H1 2020
Pipeline by Merck & Co Inc, H1 2020
Pipeline by Novartis AG, H1 2020
Pipeline by ORIC Pharmaceuticals Inc, H1 2020
Pipeline by Phanes Therapeutics Inc, H1 2020
Pipeline by Secarna Pharmaceuticals GmbH & Co. KG, H1 2020
Pipeline by Shanghai De Novo Pharmatech Co Ltd, H1 2020
Pipeline by Shanghai Henlius Biotech Inc, H1 2020
Pipeline by Xcella Biosciences Inc, H1 2020
Dormant Projects, H1 2020
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1)
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Akeso Inc, H1 2020
Pipeline by Aprilbio Co Ltd, H1 2020
Pipeline by Arcus Biosciences Inc, H1 2020
Pipeline by AstraZeneca Plc, H1 2020
Pipeline by Aurigene Discovery Technologies Ltd, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Pipeline by Calithera Biosciences Inc, H1 2020
Pipeline by Corvus Pharmaceuticals Inc, H1 2020
Pipeline by Eli Lilly and Co, H1 2020
Pipeline by Eternity Bioscience Inc, H1 2020
Pipeline by Evotec SE, H1 2020
Pipeline by Gilead Sciences Inc, H1 2020
Pipeline by Harbour BioMed, H1 2020
Pipeline by I-Mab Biopharma Co Ltd, H1 2020
Pipeline by Innate Pharma SA, H1 2020
Pipeline by InteRNA Technologies BV, H1 2020
Pipeline by iOnctura SA, H1 2020
Pipeline by Merck & Co Inc, H1 2020
Pipeline by Novartis AG, H1 2020
Pipeline by ORIC Pharmaceuticals Inc, H1 2020
Pipeline by Phanes Therapeutics Inc, H1 2020
Pipeline by Secarna Pharmaceuticals GmbH & Co. KG, H1 2020
Pipeline by Shanghai De Novo Pharmatech Co Ltd, H1 2020
Pipeline by Shanghai Henlius Biotech Inc, H1 2020
Pipeline by Xcella Biosciences Inc, H1 2020
Dormant Projects, H1 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Akeso Inc
Aprilbio Co Ltd
Arcus Biosciences Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Corvus Pharmaceuticals Inc
Eli Lilly and Co
Eternity Bioscience Inc
Evotec SE
Gilead Sciences Inc
Harbour BioMed
I-Mab Biopharma Co Ltd
Innate Pharma SA
InteRNA Technologies BV
iOnctura SA
Merck & Co Inc
Novartis AG
ORIC Pharmaceuticals Inc
Phanes Therapeutics Inc
Secarna Pharmaceuticals GmbH & Co. KG
Shanghai De Novo Pharmatech Co Ltd
Shanghai Henlius Biotech Inc
Xcella Biosciences Inc
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Akeso Inc
Aprilbio Co Ltd
Arcus Biosciences Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Corvus Pharmaceuticals Inc
Eli Lilly and Co
Eternity Bioscience Inc
Evotec SE
Gilead Sciences Inc
Harbour BioMed
I-Mab Biopharma Co Ltd
Innate Pharma SA
InteRNA Technologies BV
iOnctura SA
Merck & Co Inc
Novartis AG
ORIC Pharmaceuticals Inc
Phanes Therapeutics Inc
Secarna Pharmaceuticals GmbH & Co. KG
Shanghai De Novo Pharmatech Co Ltd
Shanghai Henlius Biotech Inc
Xcella Biosciences Inc
